Confo Therapeutics Announces Selection of First Product Candidate and Initiation of Pre-Clinical Development
Ghent, Belgium – October 15, 2020 - Confo Therapeutics today announced the selection of its first preclinical drug candidate, CFTX-1554, a compound designed to address peripheral neuropathic pain with the potential to address additional pain indications. Confo has...
Cristal Therapeutics announces a publication in ‘Chemical Science’ on CliCr® technology platform, comprising a new class of superior copper free click reagents for conjugation of small molecules, biologics, nanoparticles and other moieties
• Flagship chemistry journal describes the development of TMTHSI (CliCr®) as a superior click reagent • Cristal applies the CliCr® platform to the rational design of CriPec® nanomedicines, also enabling modular CriVac® vaccine product development • CliCr® can be...
Synaffix wins Best Platform Technology at 7th Annual World ADC Awards
AMSTERDAM, NETHERLANDS – September 22, 2020 – Synaffix B.V., a biotechnology companyenabling antibody-drug conjugates (ADCs) with best-in-class therapeutic index, announces thatit has won the “Best ADC Platform Technology” category at the 2020 World ADC...
Scenic Biotech Enters into Genetic Modifier Collaboration with Genentech
● Multi-year strategic collaboration in target discovery and therapeutic developmentbased on Scenic Biotech’s disease modifying approach● Utilises Scenic’s unique Cell-Seq platform and its proprietary data warehouse ofgenetic modifiers● Scenic Biotech will receive an...
Synaffix Sees Competitive Early In Vivo Data from ADCs Based on Proprietary Exatecan Linker-Payload
Synaffix Announces Expansion of Collaboration with ADC Therapeutics
AMSTERDAM, NETHERLANDS – July 23, 2020 – Synaffix B.V., a biotechnology company focused on enabling antibody-drug conjugates (ADCs) with superior therapeutic index based on its proprietary ADC technology platform, announces that ADC Therapeutics SA has expanded its...
Industry veterans Paul Peter Tak and Eric Meldrum join Citryll’s Board
Oss, The Netherlands, July 21, 2020 —Citryll announced its Board has been strengthened with twoindustry veterans with impressive track-records, Businesswire Citryll. Paul Peter Tak, MD, PhD served as Professor of Medicine and Chair of the Department of...
Staten Biotechnology, in collaboration with Novo Nordisk, starts dosing of anti-apoC3 antibody SST-5058 in First-in-Human Trial
Clinical trajectory initiated towards development of novel treatment for dyslipidaemia Nijmegen, The Netherlands, 21 July 2020 – Staten Biotechnology B.V. announced today the initiation of dosing of the Company’s lead asset, STT-5058, in a First-in-Human clinical...
VarmX raises €32 million in Series B financing to develop innovative reversal agent for the treatment and prevention of severe bleeding in patients on oral anticoagulants
Financing co-led by Ysios Capital and INKEF Capital, joined by Lundbeckfonden Ventures, LSP, and existing investors BioGeneration Ventures and InnovationQuarterProceeds to be used to achieve clinical proof of concept for lead compound, VMX-C001, advance program to...
Citryll completes € 18.5 M fundraise to develop CIT-013, an antibody targeting Neutrophil Extracellular Traps
Oss, The Netherlands, July 2, 2020 —Citryll announced it closed a total fundraise of € 18.5 million, led by Seventure(including their Health for Life Capital II fund), co-led by BioGeneration Ventures (BGV) with existing investors BOMBrabant Ventures, BrightGene and...